Toggle Menu

Press Room

The NHS and the cost-benefit dilemma

01/26/2010

New research by health economists at the University of York has raised concerns over any move to broaden the range of costs and economic benefits considered in the analysis of new NHS treatments.

2010 European "Advances in Renal Cancer Journalists' Award"

01/26/2010

In Canada Few options for kidney cancer patients

01/25/2010

Patient: "Forty-six thousand Canadians are diagnosed with kidney cancer a year and 16,000 will die. I know kidney cancer isn't as high profile as prostate or breast cancer, but we need access to life improving drugs."

Health care alternatives include tort reform and cross-state insurance plans

01/25/2010

Congress' health-care reform efforts to date have not given people confidence that the final outcome will meet goals such as greater access, affordability and quality, said Marie Gross, a Bedford health-care consultant. Subsequent reform efforts should pay greater attention to enhancing transparency and emphasizing patients' personal responsibility for their health.

Notes from the Eigth International Kidney Cancer Symposium

01/25/2010

Patient advocate Katherine Phillion's notes from our fall kidney cancer meeting, in Chicago.

Illinois Governor Pat Quinn Proclaims March 'Kidney Cancer Awareness Month'

01/25/2010

Obesity Tied to Common Kidney Cancer

01/24/2010

Obesity increases the risk of developing a common and virulent form of kidney cancer, a new study finds.

Canadians coming to the USA for treatment

01/23/2010

Canadian patients — there is no accurate count — seek treatment in the United States and pay out of pocket.

Antigenics seeks cancer vaccine approval in Europe

01/23/2010

Antigenics Inc. has spent between $400 million and $500 million to conduct two Phase 3 trials on its potential cancer vaccine. But the Lexington-based company never plans to send it to the U.S. Food and Drug Administration for approval.

Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study

01/22/2010

We performed fluorescent in situ hybridization (FISH) to investigate the numeric change of chromosomes 7, 17, and Y and loss of chromosome 3p in "papillary renal cell carcinomas (RCC) with extensive clear cell changes (CCC)." Consecutive cases of RCC over a 12-year period were reviewed to identify "papillary RCC with extensive CCC." Immunostaining for cytokeratin 7 and alpha-methylacyl-CoA racemase (AMACR) and FISH for chromosomes 7, 17, Y, and 3p were applied.

Previous  |  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95  |  96  |  97  |  98  |  99  |  100  |  101  |  102  |  103  |  104  |  105  |  106  |  107  |  108  |  109  |  110  |  111  |  112  |  113  |  114  |  115  |  116  |  117  |  118  |  119  |  120  |  121  |  122  |  123  |  124  |  125  |  126  |  127  |  128  |  129  |  130  |  131  |  132  |  133  |  134  |  135  |  136  |  137  |  138  |  139  |  140  |  141  |  142  |  143  |  144  |  145  |  146  |  147  |  148  |  149  |  150  |  151  |  152  |  153  |  154  |  155  |  156  |  157  |  158  |  159  |  160  |  161  |  162  |  163  |  164  |  165  |  166  |  167  |  168  |  169  |  170  |  171  |  172  |  173  |  174  |  175  |  176  |  177  |  178  |  179  |  180  |  181  |  182  |  183  |  184  |  185  |  186  |  187  |  188  |  189  |  190  |  191  |  192  |  193  |  194  |  195  |  196  |  197  |  198  |  199  |  200  |  201  |  202  |  203  |  204  |  205  |  206  |  207  |  208  |  209  |  210  |  211  |  212  |  213  |  214  |  215  |  216  |  217  |  218  |  219  |  220  |  221  |  222  |  223  |  224  |  225  |  226  |  227  |  228  |  229  |  230  |  231  |  232  |  233  |  234  |  235  |  236  |  237  |  238  |  239  |  240  |  241  |  242  |  243  |  244  |  245  |  246  |  247  |  248  |  249  |  250  |  251  |  252  |  253  |  254  |  255  |  256  |  257  |  258  |  259  |  260  |  261  |  262  |  263  |  264  |  265  |  266  |  267  |  268  |  269  |  270  |  271  |  272  |  273  |  274  |  275  |  276  |  277  |  278  |  279  |  280  |  281  |  282  |  283  |  284  |  285  |  286  |  287  |  288  |  289  |  290  |  291  |  292  |  293  |  294  |  295  |  296  |  297  |  298  |  299  |  300  |  301  |  302  |  303  |  304  |  305  |  306  |  307  |  308  |  309  |  310  |  311  |  312  |  313  |  314  |  315  |  316  |  317  |  318  |  319  |  320  |  321  |  322  |  323  |  324  |  325  |  326  |  327  |  328  |  329  |  330  |  331  |  332  |  333  |  334  |  335  |  336  |  337  |  338  |  339  |  340  |  341  |  342  |  343  |  344  |  345  |  346  |  347  |  348  |  349  |  350  |  351  |  352  |  353  |  354  |  355  |  356  |  357  |  358  |  359  |  360  |  361  |  362  |  363  |  364  |  Next
NeonCRM by Neon One